Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: A phase II randomized Study of the Southern Italy Cooperative Oncology Group

Journal of Clinical Oncology

Volumn 17, Issue 5, 1999, Pages 1526-1534

  Comella, Pasquale ^a   Frasci, Giuseppe ^a   Panza, Nicola ^a   Manzione, Luigi ^a   Lorusso, Vito ^a   Di Rienzo, Gaetano ^a   Cioffi, Riccardo ^a   De Cataldis, Giuseppe ^a   Maiorino, Luigi ^a   Bilancia, Domenico ^a   Nicolella, Gianpaolo ^a   Natale, Michele ^a   Carpagnano, Franco ^a   Pacilio, Carmen ^a   De Lena, Mario ^a   Bianco, Andrea ^a   Comella, Giuseppe ^a  

^a SAN PAOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; NAVELBINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0032949450     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.5.1526     Document Type: Article

References (33)

1. Gralla R: New directions in non-small cell lung cancer. Semin Oncol 17:20-29, 1990 (suppl 7)
2. Non-Small Cell Lung Cancer Cooperative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patient data from 52 randomised clinical trials. BMJ 311:899-909, 1995
3. Lilenbaum RC, Green MR: Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer. J Clin Oncol 11:1391-1402, 1993
4. Comis RL, Friedland DM: New chemotherapy agents in the treatment of advanced non-small cell lung cancer: An update including data from the Seventh World Conference on Lung Cancer. Lung Cancer 12:S63-S69, 1995 (suppl 2)
5. Le Chevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European Multicenter Trial including 612 patients. J Clin Oncol 12:360-366, 1994
6. Wozniak AJ, Crowley JJ, Balcezark SP, et al: Randomized phase III trial of cisplatin (CDDP) vs. CDDP plus Navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC): Report of a Southwest Oncology Group study (SWOG-9308). Proc Am Soc Clin Oncol 15:374a, 1996 (abstr)
7. 1 difluorodeoxycytidine). Cancer Res 50:4417-4422, 1990
8. 1 difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 19:45-55, 1993
9. Peters GJ, Bergman AR, Ruiz-van Haperen VW, et al: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22:72-79, 1995 (suppl 11)
10. Shewach DS, Lawrence TS: Radiosensitization of human tumor cells by gemcitabine in vitro. Semin Oncol 22:68-71, 1995 (suppl 11)
11. Abratt RP, Bezwoda WR, Falkson G, et al: Efficacy and safety profile of gemcitabine in non-small cell lung cancer: A phase II study. J Clin Oncol 12:1535-1540, 1994
12. Gatzmeier U, Sheperd FA, Le Chevalier T, et al: Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre extended phase II study. Eur J Cancer 32A:243-248, 1996
13. Perng RP, Chen YM, Ming-Liu J, et al: Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small cell lung cancer in a phase II randomized study. J Clin Oncol 15:2097-2102, 1997
14. Manegold C, Bergman B, Chemaissani A, et al: Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomised phase II study in locally advanced or metastatic non-small cell lung cancer. Ann Oncol 8:525-529, 1997
15. Crinò L, Scagliotti G, Marangolo M, et al: Cisplatin-gemcitabine combination in advanced non-small cell lung cancer: A phase II study. J Clin Oncol 15:297-303, 1997
16. Abratt RP, Bezwoda WR, Goedhals L, et al: Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small cell lung cancer. J Clin Oncol 15:744-750, 1997
17. Anton A, Carrato A, Gonzales Larriba JL, et al: Phase II activity of gemcitabine in combination with cisplatin in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 15:380a, 1996 (abstr)
18. Cardenal F, Rosell R, Anton A, et al: Gemcitabine + cisplatin versus etoposide + cisplatin in advanced non-small cell lung cancer patients: Preliminary randomized phase III results. Proc Am Soc Clin Oncol 16:458a, 1997 (abstr)
19. Frasci G, Panza N, Comella P, et al: Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small cell lung cancer. Ann Oncol 8:1045-1048, 1997
20. Ianniello G, De Cataldis G, Comella P, et al: Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable non-small cell lung carcinoma: A multicenter randomized clinical trial. Cancer 78:63-69, 1996
21. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
22. Hollen PJ, Gralla RJ, Kris MG, et al: Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale. Eur J Cancer 29A:S51-S58, 1993 (suppl 1)
23. Frasci G, Comella P, Panza N, et al: Carboplatin-oral etoposide personalized dosing in elderly NSCLC patients. Eur J Cancer 34:1710-1714, 1998
24. Simon R, Wittes RE, Ellenberg SS: Randomised phase II clinical trials. Cancer Treat Rep 69:1375-1381, 1985
25. Kaplan ES, Meier P: Non parametric estimation for incomplete observations. J Am Stat Assoc 53:557-580, 1958
26. Cox D: Regression models and life tables. J R Stat Assoc 34:187-220, 1972
27. Cartei G, Sibau A, Sacco C, et al: Gemcitabine plus cisplatin in non-small cell lung cancer. Eighth International Congress on Anti-Cancer Treatment, Paris, France, February 3-6, 1998 (abstr O32)
28. Langer CJ, Leighton JC, Comis RL, et al: Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: A phase II toxicity response and survival analysis. J Clin Oncol 13:1860-1870, 1995
29. Paesmans M, Sculier JP, Libert P, et al: Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party. Eur J Cancer 33:2326-2332, 1997
30. Rosell R, Gomez-Codina J, Camps C, et al: A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 330:153-158, 1994
31. Dillman RO, Herndon J, Seagren SL, et al: Improved survival in stage III non-small cell lung cancer: Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 88:1210-1215, 1996
32. Sause WT, Scott C, Taylor S, et al: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced unresectable non-small cell lung cancer. J Natl Cancer Inst 87:198-205, 1995
33. Roth JA, Fossella F, Komaki R, et al: A randomized trial comparing preoperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 86:673-680, 1994